Where is TRexBio located?

TRexBio is headquartered in San Francisco, United States.

How many employees does TRexBio have?

As of Aug 31, 2026, the latest employee count at TRexBio is 61.

Is TRexBio a funded company?

TRexBio is a funded company, having raised a total of $219M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of TRexBio?

TRexBio's latest funding was a $***** Series B round on Jan 27, 2026, with participation from 11 investors.

Where does TRexBio rank among its competitors?

TRexBio ranks 136th amongst 3727 active competitors, of which 1228 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of TRexBio?

TRexBio's top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

TRexBio - 2026 Company Profile, Team, Funding & Competitors

TRexBio is a public company based in San Francisco (United States), founded in 2019. It operates as a Developer of therapeutics for immunology and cancer. TRexBio has raised $219M in funding from investors like Polaris Partners, Laurion Capital and Delos Capital Partners. The company has 3727 active competitors, including 1228 funded and 865 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.

Company Details

Developer of therapeutics for immunology and cancer. The company is developing transformative therapies by using a technology that maps human tissue and manipulates Tregs and other immune cells in a tissue-specific and disease-specific fashion.

Key Metrics

Founded Year

2019

Location

San Francisco, United States

Stage

Public

Total Funding

$219M in 5 rounds

Latest Funding Round

Series B, Jan 27, 2026, $*****

Investors

Polaris Partners & 14 more

Ranked

136^th among 3727 active competitors

Employee Count

61 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3446 more

Exit Details

Public

View TRexBio's full profile

TRexBio got listed on Oct 09, 2026.

Click here to take a look at TRexBio's IPO in detail

TRexBio has raised a total funding of $219M over 5 rounds. Its latest funding round was a Series B round on Jan 27, 2026 for $*****. 11 investors participated in its latest round. TRexBio has 15 institutional investors.

Here is the list of recent funding rounds of TRexBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 27, 2026	3201374	Series B	8878949	6936461	5295397	3564285
Nov 07, 2024	6095792	Series B	5326444	7794760	8346867	Avego & 5 more
Mar 08, 2022	7934868	Series A	7198456	4970304	Polaris Partners & 1 more	SV Health Investors & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of TRexBio's funding rounds and investors

TRexBio's employee count trend

TRexBio has 61 employees as of Aug 26. Here is TRexBio's employee count trend over the years:

Uncover TRexBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TRexBio include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of TRexBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
136th	TRexBio 2019, San Francisco (United States), Public	Developer of therapeutics for immunology and cancer	$219M	Janus Henderson Investors, Laurion Capital ... & 13 others	66/100